- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: Neoplasms AND Mantle Cell Lymphoma.
Displaying page 3 of 4.
| EudraCT Number: 2020-005591-35 | Sponsor Protocol Number: INCMOR0208-101 | Start Date*: 2021-06-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibito... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted) AT (Completed) BE (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-005889-38 | Sponsor Protocol Number: UCL/10/0411 | Start Date*: 2012-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:University College London | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Acute myeloid leukaemia Myelodysplastic syndromes Therapy related AML or MDS Philadelphia positive Chronic Myeloid Leukaemia Acute lymphoblastic leukaemia Non-Hodgkin's lymphoma (follicular lymphom... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-001616-57 | Sponsor Protocol Number: ARD12130 | Start Date*: 2011-10-05 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma | |||||||||||||
| Medical condition: Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004356-30 | Sponsor Protocol Number: PCYC-1145-LT | Start Date*: 2020-03-11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Pharmacyclics Switzerland GmbH, an AbbVie company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) GR (Completed) CZ (Trial now transitioned) DE (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-005580-27 | Sponsor Protocol Number: ONC-2011-005 | Start Date*: 2013-04-06 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:ISTITUTO CLINICO HUMANITAS | ||||||||||||||||||||||||||||||||||||||
| Full Title: MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE,... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with lymphomas (any histology) relapsed after high dose chemotherapy and in complete remission or partial remission after the last CT line | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-001117-34 | Sponsor Protocol Number: APL-B-013-02 | Start Date*: 2004-10-13 |
| Sponsor Name:Pharma Mar S.A. | ||
| Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma. | ||
| Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-015498-11 | Sponsor Protocol Number: 3066K1-4438/B1771007 | Start Date*: 2011-07-29 | |||||||||||
| Sponsor Name:Wyeth Pharmaceuticals Inc, a wholled owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA | |||||||||||||
| Full Title: A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects With Relapsed, Refractory Mantle Cell Lymphoma | |||||||||||||
| Medical condition: Relapsed Refractory Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) FR (Completed) HU (Completed) DE (Completed) IT (Completed) BG (Prematurely Ended) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000715-23 | Sponsor Protocol Number: FIL_COLUMN | Start Date*: 2021-12-14 | |||||||||||
| Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
| Full Title: Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma... | |||||||||||||
| Medical condition: Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002139-41 | Sponsor Protocol Number: R1979-ONC-1625 | Start Date*: 2019-09-11 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
| Full Title: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma | |||||||||||||
| Medical condition: Follicular lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005217-38 | Sponsor Protocol Number: DSHNHL2004-2 | Start Date*: 2008-07-25 | |||||||||||
| Sponsor Name:German High Grade Non-Hodgkins Lymphoma group | |||||||||||||
| Full Title: Randomiseret forsøg der sammenligner 4 og 6 kemoterapicykler med CHOP (Cyklofosfamid, Doxorubicin, Vincristin og Prednison) i 21-dages intervaller, begge med 6 cykler immunterapi med monoklonalt an... | |||||||||||||
| Medical condition: Patients with untreated aggressive CD20+ Non-Hodgkins Lymphoma aged 18 to 60 years without major accompanying disorders with no risk factor according to IPI and no bulky disease (<7,5cm) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003340-24 | Sponsor Protocol Number: LOXO-BTK-18001 | Start Date*: 2019-08-09 | |||||||||||||||||||||
| Sponsor Name:Loxo Oncology, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-004061-87 | Sponsor Protocol Number: Debio1562-201 | Start Date*: 2016-01-25 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Debiopharm International S.A. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of No... | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) HU (Completed) BG (Completed) CZ (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2008-003389-25 | Sponsor Protocol Number: CC-5013-MCL-002 | Start Date*: 2011-04-11 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA | |||||||||||||
| Medical condition: Patients with mantle cell lymphoma are refractory to their regimen or have relapsed once or up to three times. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) DK (Completed) SE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004718-90 | Sponsor Protocol Number: UTX-TGR-205 | Start Date*: 2017-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:TG Therapeutics | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Ho... | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-Hodgkin lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) PL (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-005225-81 | Sponsor Protocol Number: VALYM | Start Date*: 2021-04-28 | ||||||||||||||||
| Sponsor Name:LYSARC | ||||||||||||||||||
| Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
| Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-005150-62 | Sponsor Protocol Number: GALEN | Start Date*: 2013-05-14 | |||||||||||||||||||||
| Sponsor Name:GELARC | |||||||||||||||||||||||
| Full Title: A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. | |||||||||||||||||||||||
| Medical condition: Phase IB: CD20 positive Follicular Lymphoma, WHO grade 1, 2 or 3a relapsed/refractory after ≥1 prior R-containing regimen Phase II: CD20 positive follicular and agressive B-cell lymphoma (Diffus... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) BE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2009-016378-34 | Sponsor Protocol Number: MI-CP204 | Start Date*: 2010-06-30 | |||||||||||||||||||||
| Sponsor Name:MedImmune LLC | |||||||||||||||||||||||
| Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies | |||||||||||||||||||||||
| Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-000771-33 | Sponsor Protocol Number: LYSARC | Start Date*: 2014-07-24 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: BIBLOS (BTK Inhibition in B-cell LymphOmaS) | |||||||||||||
| Medical condition: Patients with any type of relapsed or refractory B-cell lymphoma will be eligible in groups A and B (during the dose escalation and the expansion parts of the study) and untreated patients with man... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000302-37 | Sponsor Protocol Number: RHMCAN1278 | Start Date*: 2017-09-06 | ||||||||||||||||||||||||||
| Sponsor Name:University Hospital Southampton Foundation Trust | ||||||||||||||||||||||||||||
| Full Title: A phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies | ||||||||||||||||||||||||||||
| Medical condition: Relapsed or refractory B-Cell malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2005-005144-62 | Sponsor Protocol Number: MCL2005-01 | Start Date*: 2009-05-08 | |||||||||||||||||||||
| Sponsor Name:Klinikum der Ludwigs-Maximilians-Universität München | |||||||||||||||||||||||
| Full Title: Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma A randomized Phase ... | |||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
